← Leaderboards
Nicholas J Talley
Mayo Clinic
$2,189,145
Attributed
$2,189,145
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $676.3K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$2,189,145 · 4
By mechanism
U01$2,140,572 · 1
M01$48,573 · 3
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic
Same institution · by research overlap
- Ognjen Gajic$8,004,701
- Yuri Ann Saito Loftus$1,180,621
- Jean Fox$927
- Amy E Foxx-Orenstein$354,105
Others in their field
Top investigators on “Heterotrimeric Gtp-Binding Proteins”
- John J G Tesmer · University Of Texas Austin$11,742,105
- Robert J Lefkowitz · Duke University$10,021,648
- Mikel Garcia-Marcos · Boston University Medical Campus$9,091,168
- Gregory Gordon Tall · University Of Rochester$7,662,967
- Michael William Lark · Trevena, Inc.$7,639,642
- Georgios Skiniotis · Stanford University$7,403,961
Research focus
Heterotrimeric Gtp-Binding ProteinsMorbidity - Disease RateGeneticGlutaminaseHypersensitivityAmericanAnxietyAmitriptylineAccelerationAnalgesicsAntidepressive AgentsDisabilityDoseDouble-Blind MethodDrinkingDyspepsiaEscitalopramBaseExposure ToChronicFollow-Up StudiesFunctional DisorderGastric EmptyingMotor
Grant awards (8)
Antidepressant Therapy for Functional Dyspepsia$399,469
U01 · FY2009 · DK · contact PI
Antidepressant Therapy for Functional Dyspepsia$544,334
U01 · FY2008 · DK · contact PI
Antidepressant Therapy for Functional Dyspepsia$546,010
U01 · FY2007 · DK · contact PI
Antidepressant Therapy for Functional Dyspepsia$23,000
U01 · FY2007 · DK · contact PI
Antidepressant Therapy for Functional Dyspepsia$627,759
U01 · FY2005 · DK
EFFECT OF DESIPRAMINE AND ESCITALOPRAM IN HEALTHY INDIVIDUALS$23,694
M01 · FY2005 · RR
STUDY TO EVALUATE THE EFFECT OF ASIMADOLINE IN PATIENTS WITH FUNCTIONAL DYSPEPSI$23,221
M01 · FY2005 · RR
EFFECTS OF A 5HT-4 RECEPTOR PARTIAL AGONIST, TEGASEROD, ON POSTPRANDIAL GASTRIC$1,658
M01 · FY2005 · RR